Photo By Al Drago/CQ Roll Call The Trump administration has granted Fast Track designation to a groundbreaking — and controversial — self-amplifying mRNA (sa-mRNA) vaccine candidate targeting the H5N1 avian influenza virus. The vaccine, ARCT-2304, developed by Arcturus Therapeutics, is now in Phase 1 trials and has been positioned by federal health authorities as a front-line defense against a potential bird flu pandemic. The designation, announced April 10, was awarded by the U.S. Food and Drug Administration (FDA) in partnership with the Department of Health and Human Services and its Biomedical Advanced Research and Development Authority (BARDA). The Fast Track designation from the FDA expedites the review of drugs intended for serious or life-threatening conditions that demonstrate the potential to address unmet medical needs. This…
Click here to read the full article at The Gateway Pundit.
